IL37 and inflammatory bowel disease: Experimental studies related to IBD have shown that IL-23 drives local intestinal inflammation, and blockade of IL-23 or its receptor IL23R is associated with impaired activation of IL-23 target cells (such as TH17 cells, ILC3s, granulocytes, and natural killer cells) and reduced production of pro-inflammatory cytokines (Neurath 2019; Uhlig et al. 2006).